Yimiao Shenzhou Announces Completion of Series E Financing to Advance Commercialization of First-in-Class CAR-T Therapy IM19

January 3, 2025, Beijing, China,Beijing Yimiaoshenzhou Medical Techology Co., Ltd. (referred to as "Yimiaoshenzhou" or "the Company") announced the official completion of its Series E financing round worth hundreds of millions of RMB.. This round of financing was led byBeijing-Tianjin-Hebei Coordinated Development Industry Investment FundLeading investment,Taiping Healthcare Fund, Capital Development Group, Si Ji Qing Investment, SunNovoFollowed by multiple professional institutions. This is the 10th round of financing completed by Beijing Yimiaoshenzhou Medical Techology Co., Ltd. on the occasion of its 10th anniversary, marking a milestone and a new starting point as the company advances from clinical research to commercialization in the field of self-developed gene and cell therapies after a decade of dedication.

The funds from this round of financing will be used to support the commercialization layout of the company's first self-developed CAR-T new drug, IM19, promoting it to become a benchmark product for late-stage lymphoma CAR-T treatment in China after its approval, providing patients with a new treatment option. At the same time, the funds will also accelerate the research and development and clinical progress of new processes and products in major disease areas such as hematological tumors, solid tumors, and autoimmune diseases, helping to build a leading domestic universal CAR-T, gene editing, and other next-generation gene and cell drug technology platforms in China. The construction and implementation of an industry-leading large-scale GMP production and manufacturing base will inject strong momentum into the company’s development.

CEO of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., Dr. Ting HeExpressed: We are very grateful for the recognition and support from both new and existing shareholders. This round of financing is an important milestone in the development of Beijing Yimiaoshenzhou Medical Techology Co., Ltd. We will take this opportunity to fully advance the commercialization of our first CAR-T product, IM19, as well as the research and development layout of CAR-T therapeutic products covering major diseases such as hematological tumors, solid tumors, and autoimmune diseases. We will continue to invest in the research and development of next-generation CAR-T processes and technologies, promote technological iteration and upgrading, and ensure that Beijing Yimiaoshenzhou Medical Techology Co., Ltd. maintains a leading position in the global gene and cell drug competition. Our goal is to research and produce more new drugs and better drugs with lower costs, better efficacy, and higher safety, benefiting a wide range of patients, promoting industrial development, and serving Healthy China.

Beijing-Tianjin-Hebei Collaborative Development Industry Investment FundStated: As an investment fund focused on the coordinated development of the Beijing-Tianjin-Hebei region, Beijing Yimiaoshenzhou Medical Techology Co., Ltd.'s technological innovation and industrialization capabilities in the field of gene and cell therapy align perfectly with our strategy to support high-tech, high-growth enterprises. We believe that through this collaboration, we will not only accelerate the rapid development of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., but also contribute significantly to the coordinated growth of the cell therapy industry in the Beijing-Tianjin-Hebei region and the rise of China’s cell therapy industry.

Taiping Healthcare FundStated: As an existing shareholder, we are delighted to accompany the long-term growth of Beijing Yimiaoshenzhou Medical Techology Co., Ltd. Taiping Healthcare Fund has long been focusing on innovative medical technologies in the field of major diseases and will adhere to the investment philosophy of patient capital to help China's innovative drugs benefit more patients. After the commercial launch of Yimiaoshenzhou’s products, Taiping Healthcare Fund will continue to promote the deep integration of commercial insurance and innovative drugs, contributing Taiping’s strength to meet patients' clinical needs.

Beijing First Development Pre-incubation Growth Equity Investment FundStated: As an investment fund within the Shoufa Group system, we are delighted to once again participate in the financing of Beijing Yimiaoshenzhou Medical Technology Co., Ltd., witnessing the company's growth and progress. This round of financing will provide strong support for Yimiaoshenzhou’s research and development and commercialization efforts. We look forward to Yimiaoshenzhou forming a close collaboration with the Global Future Pharmaceutical and Health Industry Incubation Base established by Beijing Capital Science and Technology Development Group Technology Service Co., Ltd., achieving more breakthroughs in the field of gene and cell therapy, and bringing more innovative treatment options to patients suffering from serious illnesses like cancer.

Sijiqing Investment stated: As a local enterprise, Yimiao Shenzhou has always been one of the key enterprises we focus on and support. We hope to take this round of financing as an opportunity to further optimize the business environment, effectively meet the needs of enterprises, fully serve as the "local steward" for enterprises, help enterprises develop healthily and rapidly, and achieve a win-win situation in social value and economic benefits.

SunNovoWe are delighted to participate in Beijing Yimiaoshenzhou Medical Techology Co., Ltd.'s current round of financing. The company's leading position and innovative capabilities in the field of gene and cell therapy drugs have shown us tremendous potential. This round of financing will advance the company’s research and development progress in major disease areas, and we look forward to witnessing the innovation and development of China's novel drug industry together with Beijing Yimiaoshenzhou Medical Techology Co., Ltd.

The Beijing-Tianjin-Hebei Collaborative Development Industrial Investment Fund was established in February 2021 by the People's Governments of Beijing, Tianjin, and Hebei in collaboration with the China Development Bank to thoroughly implement the major national strategy of Beijing-Tianjin-Hebei collaborative development and fully leverage the guiding and amplifying role of fiscal funds from the three regions. The initial scale of the fund is 4.15 billion yuan, with a focus on supporting fields related to regional scientific and technological innovation and high-end manufacturing.

Taiping Medical and Health Fund is a private equity investment fund managed by Taiping Innovation, a subsidiary of China Taiping Insurance Group, with a registered size of 10 billion yuan. Taiping Group's equity investment business has long focused on the medical and health industry. Under the guidance of the Healthy China strategy, Taiping Innovation closely aligns its investments with Taiping Group’s core insurance business to achieve mutual empowerment between fund investments and the insurance main business, supporting the creation of China Taiping’s “Insurance + Medical Care and Elderly Care” ecosystem. In managing this fund, Taiping Innovation adopts an F+D investment strategy, focusing on areas such as biopharmaceuticals and pharmaceutical outsourcing, medical devices and diagnostics, medical services, biotechnology, and medical informatization, extending into health technology and health consumption.

Beijing Capital Science and Technology Development Group was established in December 2014. It is an important carrier for Beijing to accelerate the reform of the science and technology system, promote the reform of public institutions, and establish a "corporate" model for the "pre-incubation" of scientific and technological achievements. It is committed to building a "pre-incubation" innovation service platform with global influence, promoting the landing of major scientific and technological achievement projects in Beijing that have significant value both domestically and internationally and are at the stage of application exploration or preliminary research.

Sijiqing Investment is an investment company under Sijiqing Town, Haidian District, Beijing. Relying on nearly one million square meters of high-quality park carrier resources within the Sijiqing Town area, it closely follows the overall deployment of the 2024 Haidian District Economic and Social High-Quality Development Conference regarding Haidian District’s commitment to "adhering to the leadership of scientific and technological innovation, firmly shouldering the banner of artificial intelligence's preemptive development, continuously strengthening the pharmaceuticals and health industry, and striving to cultivate more innovative industrial clusters with technical dominance and global competitiveness." The company focuses on industries such as pharmaceuticals and health, cybersecurity, and aerospace information. By establishing industrial funds, it drives the transformation of scientific and technological achievements in Haidian District and helps Sijiqing Town rapidly achieve a high-level industrial cluster.

Beijing Sunshine Nohe Drug Research Co., Ltd., as a leading Contract Research Organization (CRO) in drug development services in China, not only possesses 36,300 square meters of research and development laboratories and over 80% of its staff dedicated to R&D, but has also established advanced technology platforms across multiple fields such as drug discovery, pharmaceutical research, clinical trials, and bioanalysis. The company maintains strong innovation capabilities, with 12 self-initiated innovative drug projects in its pipeline, targeting various therapeutic areas including pain management, nephrology and dialysis, and oncology supportive care. Several projects have no equivalent products currently on the market in China, showcasing robust R&D momentum and the ability to translate research into results. By continuously increasing investment in R&D and technological innovation, the company provides comprehensive one-stop drug development services to pharmaceutical enterprises and research institutions in China, committed to helping domestic pharmaceutical manufacturers accelerate import substitution and achieve independent innovation.

Beijing Yimiaoshenzhou Medical Techology Co., Ltd. was founded in 2015, headquartered in Beijing, with the mission of "making cancer no longer an incurable disease." It is a leading innovative pharmaceutical company at the commercialization stage, focusing on applying cutting-edge gene and cell drug technologies to treat major diseases such as cancer and autoimmune disorders. To date, the company has completed 10 rounds of strategic financing and owns a one-stop proprietary gene and cell drug R&D and industrialization platform. It possesses multiple core technologies, won the highest prize (Excellence Award) in the finals of China’s Disruptive Technology Innovation Competition, obtained seven clinical trial approvals for Class 1 new drugs, and received Beijing's first Drug Manufacturing License for gene and cell drugs. Its R&D pipeline covers hematological malignancies such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, colorectal cancer, and melanoma, establishing itself as a leader in the gene and cell drug industry.

The company has undertaken more than 10 national and provincial scientific research projects, including the Special Project of the Ministry of Science and Technology's Key R&D Program, the National Health Commission's Science and Technology Innovation - 2030 Major Project, the National Creation Center’s Cell Therapy “Challenge Leaderboard” Technology Tackling Project, and Beijing's Major Science and Technology Special Projects. It has obtained important qualifications such as a National High-tech Enterprise, a Beijing "Specialized, Precise, Unique, and Innovative" Enterprise, a Zhongguancun Frontier Technology Enterprise, a Zhongguancun High-tech Enterprise, and a Postdoctoral Research Workstation. The team has been honored with awards such as Beijing Science and Technology Nova, Zhongguancun High-end Leading Talent, Beijing Outstanding Engineer, Beijing Haidian Haiying Talent, Beijing Daxing Xinguomen Leading Talent, the Gold Award (First Place) in Tsinghua University's President's Cup Innovation Challenge, MIT's 35 Innovators Under 35, and Fortune Magazine’s 40 Under 40 Business Elites.